These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 27943234)

  • 1. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors.
    Zarbo A; Belum VR; Sibaud V; Oudard S; Postow MA; Hsieh JJ; Motzer RJ; Busam KJ; Lacouture ME
    Br J Dermatol; 2017 Jun; 176(6):1649-1652. PubMed ID: 27943234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
    J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.
    Makarious D; Horwood K; Coward JIG
    Eur J Cancer; 2017 Sep; 82():128-136. PubMed ID: 28666240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 inhibitor induced alopecia areata.
    Guidry J; Brown M; Medina T
    Dermatol Online J; 2018 Dec; 24(12):. PubMed ID: 30677804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of toxicities of immune checkpoint inhibitors.
    Spain L; Diem S; Larkin J
    Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alopecia areata as an immune-related adverse event of immune checkpoint inhibitors: A review.
    Antoury L; Maloney NJ; Bach DQ; Goh C; Cheng K
    Dermatol Ther; 2020 Nov; 33(6):e14171. PubMed ID: 32799412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of immunotherapy-induced immune-related adverse events.
    Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
    Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors.
    Ornstein MC; Calabrese C; Wood LS; Kirchner E; Profusek P; Allman KD; Martin A; Kontzias A; Grivas P; Garcia JA; Calabrese LH; Rini BI
    Clin Genitourin Cancer; 2019 Jun; 17(3):177-182. PubMed ID: 30824360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dermatologic toxicities of immune checkpoint inhibitors].
    Sibaud V; Boulinguez S; Pagès C; Riffaud L; Lamant L; Chira C; Boyrie S; Vigarios E; Tournier E; Meyer N
    Ann Dermatol Venereol; 2018 May; 145(5):313-330. PubMed ID: 29678394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 checkpoint inhibition: Toxicities and management.
    Hahn AW; Gill DM; Agarwal N; Maughan BL
    Urol Oncol; 2017 Dec; 35(12):701-707. PubMed ID: 28889921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy.
    King GT; Sharma P; Davis SL; Jimeno A
    Drugs Today (Barc); 2018 Feb; 54(2):103-122. PubMed ID: 29637937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
    Plachouri KM; Vryzaki E; Georgiou S
    Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remote-onset alopecia areata attributed to ipilimumab.
    Pearson DR; Lewis K; Alkousakis T
    Cutis; 2019 Dec; 104(6):E25-E27. PubMed ID: 31939941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
    Bhardwaj M; Chiu MN; Pilkhwal Sah S
    Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
    Belkhir R; Burel SL; Dunogeant L; Marabelle A; Hollebecque A; Besse B; Leary A; Voisin AL; Pontoizeau C; Coutte L; Pertuiset E; Mouterde G; Fain O; Lambotte O; Mariette X
    Ann Rheum Dis; 2017 Oct; 76(10):1747-1750. PubMed ID: 28600350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab.
    Kethireddy N; Thomas S; Bindal P; Shukla P; Hegde U
    J Oncol Pharm Pract; 2021 Jan; 27(1):207-211. PubMed ID: 32390537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
    Boutros C; Tarhini A; Routier E; Lambotte O; Ladurie FL; Carbonnel F; Izzeddine H; Marabelle A; Champiat S; Berdelou A; Lanoy E; Texier M; Libenciuc C; Eggermont AM; Soria JC; Mateus C; Robert C
    Nat Rev Clin Oncol; 2016 Aug; 13(8):473-86. PubMed ID: 27141885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.